The announced plan is that bisatrene will first be approved as a single agent for EMD AML. That was announced long before the recent cardioprotection findings.
If there's a change in plan, it hasn't been announced.
I guess RAC will proceed as already announced because the 505(b)(2) pathway is the fastest route to approval.
As for administering two drugs separately rather than coformulated, I have no idea whether the coformulation has advantages other than convenience and avoiding errors. I have zero medical background.
==================
There's no way to edit previous HC posts later than about 30 seconds from having posting them.
The announced plan is that bisatrene will first be approved as a...
-
- There are more pages in this discussion • 203 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add RAC (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$1.81 |
Change
-0.010(0.55%) |
Mkt cap ! $307.3M | |||
| Open | High | Low | Value | Volume |
| $1.83 | $1.84 | $1.78 | $271.2K | 150.5K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 500 | $1.80 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.81 | 349 | 1 |
View Market Depth
| Last trade - 16.10pm 27/06/2024 (20 minute delay) ? |
| RAC (ASX) Chart |